19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
June 2019 in “Journal of Drug Delivery and Therapeutics” This review highlights the use of finasteride, a 5alpha-reductase inhibitor, for treating benign prostatic hyperplasia and male pattern hair loss, noting that it may cause male sexual dysfunction but usually with tolerable side effects that decrease over time, not requiring treatment discontinuation.
65 citations
,
October 1999 in “Journal of The American Academy of Dermatology” In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.
60 citations
,
December 1998 in “Clinical Pharmacology & Therapeutics” Both drugs lower DHT levels, with GI198745 being more effective.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” 61 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism”